What’s Happening with Big Pharma and Neuroscience Development?
Date & Location
August 15, 2013
McGovern Institute at MIT
What is going on?! In the last decade, many pharmaceutical companies have given up on neuroscience R&D. Finding funding for neurology-oriented startup biotech companies has been challenging for some time. Meanwhile, some companies have “doubled down” on neurology.
At BIO 2012, Governor Patrick announced the formation of the Massachusetts Neuroscience Consortium, “…a pioneering new model that is designed to leverage Massachusetts’ rich environment for purposes of accelerating early-stage research available to the pharmaceutical industry, introducing academic researchers to the challenges of targeted research, and facilitating industry-academic collaborations.” Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, LLC, Merck, Pfizer and Sunovion. In April of this year, President Obama announced $100 million in federal funding for the BRAIN Project, “…a project to speed up the development and application of technologies that will help researchers create dynamic brain imaging, in order to learn how individual brain cells and complex neural circuits interact.
So why do some see neuroscience as vast opportunity and some see it as a black hole? Come hear leaders from academic research, big pharma and the investment community discuss this timely topic at MIT’s McGovern Institute.
5:30-6:30pm: Cocktails, Hors d'oeuvres and Networking
6:30-8:00pm: Panel Discussion
Liam Ratcliffe, MD PhD, General Partner, New Leaf Ventures
· Guoping Feng, PhD Poitras Professor of Neuroscience, McGovern Institute for Brain Research at MIT
- Mike Ehlers, MD, PhD | Neuroscience Chief Scientific Officer, Pfizer
The Bioscience Network (TBN)
Where you are the future of life sciences
TBN is a non-profit organization providing networking and professional growth to individuals in the Bioscience industries.